Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer
We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who recei...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/3/517 |
| _version_ | 1797488855524311040 |
|---|---|
| author | Koichiro Nakajima Hiromitsu Iwata Yukiko Hattori Kento Nomura Kensuke Hayashi Toshiyuki Toshito Yukihiro Umemoto Shingo Hashimoto Hiroyuki Ogino Yuta Shibamoto |
| author_facet | Koichiro Nakajima Hiromitsu Iwata Yukiko Hattori Kento Nomura Kensuke Hayashi Toshiyuki Toshito Yukihiro Umemoto Shingo Hashimoto Hiroyuki Ogino Yuta Shibamoto |
| author_sort | Koichiro Nakajima |
| collection | DOAJ |
| description | We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60–63 Gy (relative biological effectiveness equivalents; RBE)/20–21 fractions) (<i>n</i> = 343) or NFPT (74–78 Gy (RBE)/37–39 fractions) (<i>n</i> = 296) between 2013 and 2016 were analyzed. The minimum clinically important difference (MCID) threshold was defined as one-half of a standard deviation of the baseline value. The median follow-up was 56 months and 83% completed questionnaires at 36 months. Clinically meaningful score deterioration was observed in the urinary domain at 1 month in both groups and in the sexual domain at 6–36 months in the NFPT group, but not observed in the bowel domain. At 36 months, the mean score change for urinary summary was −0.3 (MHPT) and −1.6 points (NFPT), and that for bowel summary was +0.1 and −2.0 points; the proportion of patients with MCID was 21% and 24% for urinary summary and 18% and 29% for bowel summary. Overall, MHPT had small negative impacts on QOL over three years, and the QOL after MHPT and NFPT was similar. |
| first_indexed | 2024-03-10T00:08:13Z |
| format | Article |
| id | doaj.art-8412d08119e045a2a109a1fbdbb1d70a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:08:13Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8412d08119e045a2a109a1fbdbb1d70a2023-11-23T16:04:09ZengMDPI AGCancers2072-66942022-01-0114351710.3390/cancers14030517Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate CancerKoichiro Nakajima0Hiromitsu Iwata1Yukiko Hattori2Kento Nomura3Kensuke Hayashi4Toshiyuki Toshito5Yukihiro Umemoto6Shingo Hashimoto7Hiroyuki Ogino8Yuta Shibamoto9Department of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya 462-8508, JapanDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya 462-8508, JapanDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya 462-8508, JapanDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya 462-8508, JapanDepartment of Proton Therapy Technology, Nagoya Proton Therapy Center, Nagoya 462-8508, JapanDepartment of Proton Therapy Physics, Nagoya Proton Therapy Center, Nagoya 462-8508, JapanDepartment of Urology, Nagoya City University West Medical Center, Nagoya 462-8508, JapanDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, JapanDepartment of Radiation Oncology, Nagoya Proton Therapy Center, Nagoya City University West Medical Center, Nagoya 462-8508, JapanDepartment of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, JapanWe retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60–63 Gy (relative biological effectiveness equivalents; RBE)/20–21 fractions) (<i>n</i> = 343) or NFPT (74–78 Gy (RBE)/37–39 fractions) (<i>n</i> = 296) between 2013 and 2016 were analyzed. The minimum clinically important difference (MCID) threshold was defined as one-half of a standard deviation of the baseline value. The median follow-up was 56 months and 83% completed questionnaires at 36 months. Clinically meaningful score deterioration was observed in the urinary domain at 1 month in both groups and in the sexual domain at 6–36 months in the NFPT group, but not observed in the bowel domain. At 36 months, the mean score change for urinary summary was −0.3 (MHPT) and −1.6 points (NFPT), and that for bowel summary was +0.1 and −2.0 points; the proportion of patients with MCID was 21% and 24% for urinary summary and 18% and 29% for bowel summary. Overall, MHPT had small negative impacts on QOL over three years, and the QOL after MHPT and NFPT was similar.https://www.mdpi.com/2072-6694/14/3/517proton therapyprostate cancermoderately hypofractionationquality of lifeEPIC-50 |
| spellingShingle | Koichiro Nakajima Hiromitsu Iwata Yukiko Hattori Kento Nomura Kensuke Hayashi Toshiyuki Toshito Yukihiro Umemoto Shingo Hashimoto Hiroyuki Ogino Yuta Shibamoto Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer Cancers proton therapy prostate cancer moderately hypofractionation quality of life EPIC-50 |
| title | Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer |
| title_full | Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer |
| title_fullStr | Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer |
| title_full_unstemmed | Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer |
| title_short | Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer |
| title_sort | patient reported quality of life outcomes after moderately hypofractionated and normofractionated proton therapy for localized prostate cancer |
| topic | proton therapy prostate cancer moderately hypofractionation quality of life EPIC-50 |
| url | https://www.mdpi.com/2072-6694/14/3/517 |
| work_keys_str_mv | AT koichironakajima patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT hiromitsuiwata patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT yukikohattori patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT kentonomura patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT kensukehayashi patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT toshiyukitoshito patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT yukihiroumemoto patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT shingohashimoto patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT hiroyukiogino patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer AT yutashibamoto patientreportedqualityoflifeoutcomesaftermoderatelyhypofractionatedandnormofractionatedprotontherapyforlocalizedprostatecancer |